Search results for "Anti-cancer drug"

showing 10 items of 10 documents

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

2020

Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelia…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyhalloysite nanotubesengineering.materialHalloysiteProdigiosin03 medical and health scienceschemistry.chemical_compoundcomet assaylcsh:TP248.13-248.65Cytotoxic T cellcancerOriginal Researchgenotoxic effectanti-cancer drugsbiologyChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologybiology.organism_classificationmalignant cellsComet assay030104 developmental biologyprodigiosinDrug deliveryToxicitySerratia marcescensdrug deliveryCancer researchengineering0210 nano-technologyDrug carrierBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells

2017

// Giuliana Gatti 1, * , Valeria Lucini 2, * , Silvana Dugnani 2 , Angela Calastretti 1 , Gilberto Spadoni 3 , Annalida Bedini 3 , Silvia Rivara 4 , Marco Mor 4 , Gianfranco Canti 1 , Francesco Scaglione 2 and Annamaria Bevilacqua 1 1 Department of Medical Biotechnology and Translational Medicine, Universita degli Studi di Milano, Milan, Italy 2 Department of Oncology and Hemato-oncology, Universita degli Studi di Milano, Milan, Italy 3 Department of Biomolecular Sciences, Universita degli Studi di Urbino “Carlo Bo”, Urbino, Italy 4 Department of Food and Drug, Universita degli Studi di Parma, Parma, Italy * Authors contributed equally to this work Correspondence to: Annamaria Bevilacqua, e…

0301 basic medicineanti-cancer drugs; breast cancer; melanoma; melatonin analogues; melatonin receptorsPharmacologyMelatonin03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerIn vivomelatonin receptorsmelanomaMedicineCytotoxic T cellReceptoranti-cancer drugsbusiness.industryMelanomamelatonin analoguesmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisCancer cellbusinesshormones hormone substitutes and hormone antagonistsResearch Papermedicine.drugOncotarget
researchProduct

Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medi…

2017

A method based on micellar liquid chromatography to quantify the tyrosine kinase inhibitors axitinib, lapatinib and afatinib in plasma is reported. The sample pretreatment was a simple 1/5-dilution in a pure micellar solution, filtration and direct injection, without requiring extraction or purification steps. The three drugs were resolved from the matrix in 17 min, using an aqueous solution of 0.07 M sodium dodecyl sulfate – 6.0% 1-pentanol, buffered at pH 7 with 0.01 M phosphate salt as mobile phase, running under isocratic mode at 1 mL/min through a C18 column. The detection was performed by absorbance at 260 nm. An accurate mathematical relationship was established between the retention…

0301 basic medicineretentionBioanalysisIndazolesAxitinibbioanalysisClinical BiochemistryAntineoplastic AgentsAfatinib01 natural sciencesBiochemistryMicelleAnalytical ChemistryMatrix (chemical analysis)03 medical and health scienceschemistry.chemical_compoundDrug StabilityPulmonary surfactantLimit of DetectionNeoplasmsdirect injectionHumansSodium dodecyl sulfateMicellesDetection limitAqueous solutionChromatographyChemistry010401 analytical chemistryImidazolesReproducibility of ResultsmodelingLapatinibCell BiologyGeneral Medicine0104 chemical sciences030104 developmental biologyanti-cancer drugMicellar liquid chromatographyLinear ModelsQuinazolinesoptimizationChromatography LiquidJournal of Chromatography B
researchProduct

3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.

2011

During a screening for compounds that could act against Mycobacterium tuberculosis, a series of new cellular antiproliferative agents was identified. The most cytotoxic molecules were evaluated against a panel of human cell lines derived from hematological and solid human tumors. In particular, (E)-2-(1H-benzo[d] [1,2,3]triazol-1-yl)-3-(4-methoxyphenyl)acrylonitrile (1) was found to be of a potency comparable to etoposide and greater than 6-mercaptopurine in all cell lines tested. Accordingly, a synthesis of a new series of (E)-2-(5,6-dichloro-1H-benzo[d] [1,2,3]triazol-1-yl)-3-(4-R-phenyl)acrylonitriles was conducted in order to extend the studies of structure-activity relationship (SAR) f…

Models MolecularMagnetic Resonance SpectroscopyMolecular modelStereochemistryAnti-cancer drugsBinding CompetitiveGas Chromatography-Mass SpectrometryAnti-cancer drugchemistry.chemical_compoundStructure-Activity RelationshipTubulinAnti-cancer drugs; drug design and development; computer assisted drug designDrug DiscoveryK562 CellmedicineStructure–activity relationshipHumansdrug design and developmentPharmacologybiologyAcrylonitrileChemistryArylOrganic ChemistryCell Cyclecomputer assisted drug designGeneral MedicineCell cycleTriazolesTubulinPodophyllotoxinCell cultureTubulin Binding Agentbiology.proteinTriazoleColchicineK562 CellsHumanmedicine.drugEuropean journal of medicinal chemistry
researchProduct

Triphenyltin(IV) 2-[(E)-2-(aryl)-1-diazenyl]benzoates as anticancer drugs: Synthesis, structural characterization, in vitro cytotoxicity and study of…

2009

Summary: Triphenyltin(IV) complexes of composition [Ph3SnL 1H]n (1) and [Ph3SnL2H]n (2) (where L1H=2-[(E)-2-(3-formyl-4-hydroxyphenyl)-1-diazenyl] benzoate and L2H = 2-[(E)-2-(4-Hydroxy-5-methylphenyl)-1-diazenyl] benzoate) were synthesized and characterized by spectroscopic (1H, 13C and 119Sn NMR, IR, 119Sn Mössbauer) techniques in combination with elemental analysis. The molecular structures and geometries of the complexes (1 and 2) were fully optimized using the quantum mechanical method (PM3). Complexes (1 and 2) were found to exhibit stronger cytotoxic activity in vitro across a panel of human tumour cell lines viz., A498, EVSA-T, H226, IGROV, M19 MEL, MCF-7 and WIDR. The test compound…

Models MolecularMagnetic Resonance SpectroscopySpectrophotometry InfraredStereochemistryTriphenyltin(IV) 2-[(E)-2-(4-Hydroxy-5-methylphenyl)-1-diazenyl]benzoateAntineoplastic AgentsCrystallography X-RayThymidylate synthaseAnti-cancer drugTriphenyltin(IV) benzoateCell Line TumorRibonucleotide ReductasesOrganotin CompoundsHumansPharmacology (medical)Pharmacologychemistry.chemical_classificationBinding SitesbiologyCell DeathChemistryTopoisomeraseThymidylate SynthaseIn vitroBenzoatesRibonucleotide reductaseEnzymeOncologyDocking (molecular)Cell cultureSettore CHIM/03 - Chimica Generale E InorganicaDocking studiebiology.proteinQuantum TheoryThermodynamicsTriphenyltin(IV) 2-[(E)-2-(3-formyl-4-hydroxyphenyl)-1-diazenyl]benzoateDrug Screening Assays AntitumorCell line
researchProduct

Molecular basis of the interaction of novel tributyltin(IV) 2/4-[(E)-2-(aryl)-1-diazenyl] benzoates endowed with an improved cytotoxic profile: Synth…

2010

A series of tributyltin(IV) complexes based on 2/4-[(E)-2-(aryl)-1-diazenyl]benzoate ligands was synthesized, wherein the position of the carboxylate and aryl substituents (methyl, tert-butyl and hydroxyl) varies. The complexes, Bu(3)SnL(1-4)H (1-4), have been structurally characterized by elemental analysis and IR, NMR ((1)H, (13)C, and (119)Sn) and (119)Sn Mossbauer spectroscopy. All have a tetrahedral geometry in solution and a trigonal bipyramidal geometry in the solid-state, except for Bu(3)SnL(4)H (4) that was ascertained to have tetrahedral coordination by X-ray crystallography. Cytotoxicity studies were carried out on human tumor cell lines A498 (renal cancer), EVSA-T (mammary cance…

Models MolecularQuantitative structure–activity relationshipMagnetic Resonance SpectroscopyStereochemistryCell SurvivalANTITUMOR-ACTIVITYHydrophobicityQuantitative Structure-Activity RelationshipAntineoplastic AgentsCrystallography X-RayBiochemistryBenzoatesVALIDATIONInorganic Chemistrychemistry.chemical_compoundAnti-cancer drugCell Line TumorOrganotin CompoundsTRIORGANOTIN(IV) COMPLEXESHumansCRYSTAL-STRUCTURESCarboxylateOPTIMIZATIONArylazobenzoateSpectroscopyX-ray crystallographyMolecular StructureQSARArylTetrahedral molecular geometryNuclear magnetic resonance spectroscopyBenzoatesTributyltin(IV) compoundTrigonal bipyramidal molecular geometryMOSQUITO LARVAEchemistryCELL-DEATHDocking (molecular)Settore CHIM/03 - Chimica Generale E InorganicaDocking studies RIBONUCLEOTIDE REDUCTASE INHIBITORSEMIEMPIRICAL METHODSTrialkyltin CompoundsCell lineAEDES-AEGYPTI
researchProduct

Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction …

2009

Dibutyltin(IV) complexes of composition Bu2Sn (LH)2, where LH is a carboxylate residue derived from 2-[(E)- (5-tert-butyl-2- hydroxyphenyl)diazenyl]benzoate (L1H) with water molecule (1), 4-[(E)-(5-tert-butyl-2-hydroxyphenyl) diazenyl]benzoate (L2H) (2) and 4-[(E)-(4-hydroxy-5- methylphenyl)diazenyl]benzoate (L3H) (3), were synthesized and characterized by spectroscopic (1H, 13C and 119Sn NMR, IR, 119Sn Mössbauer) techniques. A full characterization was accomplished from the crystal structure of complex 1. The molecular structures and geometries of the complexes (1a i.e. 1 without water molecule and 3) were fully optimized using the quantum mechanical method (PM6). Complexes 1 and 3 were fo…

Models MolecularStereochemistryMolecular ConformationCrystallography X-RayLigandsThymidylate synthaseAnti-cancer drugchemistry.chemical_compoundCell Line TumorRibonucleotide ReductasesOrganotin CompoundsMoleculeHumansPharmacology (medical)CarboxylateArylazobenzoateSpectroscopyPharmacologychemistry.chemical_classificationBinding SitesbiologyCell DeathTopoisomeraseHydrogen BondingThymidylate SynthaseIn vitroEnzymesRibonucleotide reductaseEnzymeDNA Topoisomerases Type IIOncologychemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Docking studieDibutyltin(IV) compoundbiology.proteinQuantum TheoryDrug Screening Assays AntitumorCell lineInvestigational new drugs
researchProduct

An in vitro comparative assessment with a series of new triphenyltin(IV) 2-/4-[(E)-2-(aryl)-1-diazenyl]benzoates endowed with anticancer activities: …

2012

Four new triphenyltin(IV) complexes of composition Ph 3SnLH (where LH = 2-/4-[(E)-2-(aryl)-1-diazenyl]benzoate) (1-4) were synthesized and characterized by spectroscopic ( 1H, 13C and 119Sn NMR, IR, 119Sn Mössbauer) techniques in combination with elemental analysis. The 119Sn NMR spectroscopic data indicate a tetrahedral coordination geometry in non-coordinating solvents. The crystal structures of three complexes, Ph 3SnL 1H (1), Ph 3SnL 3H (3), Ph 3SnL 4H (4), were determined. All display an essentially tetrahedral geometry with angles ranging from 93.50(8) to 124.5(2)°; 119Sn Mössbauer spectral data support this assignment. The cytotoxicity studies were performed with complexes 1-4, along…

Models MolecularTriphenyltin(IV) benzoatesCell SurvivalStereochemistryMolecular ConformationQuantitative Structure-Activity RelationshipAntineoplastic AgentsStereoisomerismCrystal structureCrystallography X-RayBenzoatesBiochemistryInorganic ChemistryAnti-cancer drugInhibitory Concentration 50chemistry.chemical_compoundCell Line TumorOrganotin CompoundsHumansCytotoxicityCoordination geometryQSARHydrogen bondArylTetrahedral molecular geometryHydrogen BondingStereoisomerismBenzoateschemistrySettore CHIM/03 - Chimica Generale E InorganicaCell lineTriphenyltin(IV) 2-/4-[(E)-2-(aryl)-1-diazenyl]benzoateJournal of Inorganic Biochemistry
researchProduct

4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.

2014

Hsp90 is considered an interesting therapeutic target for anticancer drug development. Here we describe a new class of 4,5,6,7-tetrahydro-isoxazolo-[4,5-c]-pyridine compounds. A small library of derivatives has been synthesized and investigated. Some reported compounds show interesting properties combining both notable binding to Hsp90 and potent cell growth inhibitory activity. N-5 substitution with a 2,4 resorcinol carboxamide appears crucial for activity. Moreover, a derivative bearing a hydroxamic acid residue bound to C-3 amide portion was found to inhibit both Hsp90 and HDAC6.

Spectrometry Mass Electrospray IonizationMagnetic Resonance Spectroscopymedicine.drug_classStereochemistryPyridinesCarboxamideApoptosisResorcinolAnti-cancer drugschemistry.chemical_compoundResidue (chemistry)AmideDrug DiscoveryHeat shock protein 90 Anti-cancer drugs 4567-Tetrahydro-isoxazolo-[45-c]- pyridinesmedicineCytotoxic T cellHumansHeat shock protein 90HSP90 Heat-Shock ProteinsPharmacologyHydroxamic acidChemistryCell growthOrganic ChemistryGeneral MedicineNuclear magnetic resonance spectroscopy4 5 6 7-Tetrahydro-isoxazolo-[4 5-c]-pyridinesFlow CytometrySettore CHIM/08 - Chimica Farmaceuticahsp90Settore BIO/14 - Farmacologia4 5 6 7-Tetrahydro-isoxazolo-[4 5-c]-pyridines; Anti-cancer drugs; Heat shock protein 90;K562 CellsCell DivisionEuropean journal of medicinal chemistry
researchProduct

Diabetes and cancer: A critical appraisal of the pathogenetic and therapeutic links.

2014

Diabetes and cancer represent two common, multifactorial, chronic and potentially fatal diseases, not infrequently co-diagnosed in the same patient. Epidemiological data demonstrate significant increases of the cancer incidence in patients with obesity and diabetes, which is more evident for certain site-specific cancers. Although there is increasing evidence that strongly indicates an augmented risk of cancer in diabetic patients, several confounding factors complicate the ability to precisely assess the risk. Mainly in insulin-resistant states (such as in type 2 diabetes mellitus and in metabolic syndrome), direct associations between obesity-related hyperinsulinemia and increasing circul…

business.industryGeneral NeuroscienceType 2 Diabetes MellitusCancerGeneral MedicineReviewmedicine.diseaseBioinformaticsmedicine.disease_causeObesityGeneral Biochemistry Genetics and Molecular Biologyinsulin-resistant stateanti-cancer drugdiabeteDiabetes mellitusanti-diabetic medicationmedicineHyperinsulinemiacancerGeneral Pharmacology Toxicology and PharmaceuticsMetabolic syndromeAdverse effectCarcinogenesisbusinessriskBiomedical reports
researchProduct